DARPA-backed team creates ultrasound-based neuromodulation implants

DARPA's former headquarters in Arlington, VA

DARPA-backed scientists have tested tiny ultrasound-based implants in rodents, which, if it translates to humans, could potentially surmount multiple hurdles in human neuromodulation.

The agency’s Electrical Prescriptions, or ElectRx, program aims to improve neuromodulation by overcoming challenges, such as making implants suitable for long-term use and implants small enough to use in small nerves.

A DARPA-funded team led by University of California, Berkeley scientists developed a safe wireless neuromodulation devices that are small enough to be implanted in individual nerves, DARPA said in a statement. They tested the implants, dubbed “neural dust,” in rodents.The findings were published this week in the journal Neuron.

Event

Join the world's top medtech executives virtually for the leading event in medtech — The Virtual MedTech Conference by AdvaMed

Expect the same high-quality education, world-class speakers and valuable business development in a virtual format. Experience more of the conference with on demand content and partnering, as well as livestreamed sessions.

Each “neural dust mote” comprises two electrodes to measure nerve signals, a transistor that amplifies the signal and a piezoelectric crystal that has two functions: wirelessly transferring the data to an external transceiver board and converting mechanical energy from externally generated ultrasound into electrical energy for the implant to work.

The piezoelectric crystal means that the implants do not need batteries, thereby eliminating the need for further surgeries. And using ultrasound rather than traditional radio waves for communication and power brings other advantages too: “By using ultrasound to communicate with the neural dust, the sensors can be made smaller and placed deeper inside the body, by needle injection or other non-surgical approaches,” said Doug Weber, program manager for ElectRx, in the statement.

The team made the “neural dust” devices, which measure 0.8 mm by 3 mm by 1 mm, from commercially available parts. But they could go even smaller if they had custom parts, they said. The team will now develop even smaller “neural dust” implants, focusing on biocompatibility, portability of the transceiver board and ensuring the system can distinguish between signals when multiple sensors are implanted close to each other, such as within a nerve bundle.

- here's the statement

Related Articles:
Boston Scientific snatches up Cosman Medical to gain ground in neuromodulation
Endonovo inks $21.5M deal to pick up electroceuticals maker Rio Grande
Abbott, St. Jude’s $25B tie-up delayed by FTC request

Read more on

Suggested Articles

Chi-Med has detailed plans to seek approval from the FDA later this year in part on the strength of data from Chinese phase 3 trial.

Takeda tapped Roche’s Foundation Medicine to develop tissue- and blood-based companion diagnostic tests for its portfolio of lung cancer therapies.

The clamor for more transparency from the leading pandemic vaccine contenders has been getting louder.